the goal of product development
for new healthcare technologies is to maximize return on investment by achieving optimal pricing, reimbursement and utilization, while ensuring appropriate patient access. This goal is becoming an ever more difficult challenge, with the growing complexity, regulation and cost containment of todays global healthcare environment combined with the increasing cost of product development.
product development teams
for pharmaceutical, biotechnology, medical device and diagnostic testing products all face the same challenge: how best to characterize, quantify and communicate the value and affordability of their products in order to achieve the target return on investment.
achieving optimal market access
(optimal pricing, reimbursement and utilization) requires a strategic approach to building, organizing, integrating and deploying a market access capability within the organization.
michael pollock,
President of Reynolds Pollock & Associates, has a unique background in the biopharmaceutical industry, having held senior positions both in Sales & Marketing and in Health Economics. He brings a blend of strategic vision, commercial focus and research discipline to the ongoing challenge of achieving commercial success through optimal market access.